New Elite Feature: Screen & Chart at the same time

Jyong Biotech Ltd.

Contributing Author

Recent Articles by Jyong Biotech Ltd.

May-15	Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 MENS GlobeNewswire
Apr-28	Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio MENS GlobeNewswire
Mar-27	Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 MENS GlobeNewswire
Feb-12	Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia MENS GlobeNewswire
Jan-30	Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value MENS -7.81% GlobeNewswire
Dec-19	Jyong Biotech Responds to Share Price and Volume Movement MENS GlobeNewswire
Dec-04	Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry MENS GlobeNewswire
Nov-24	Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs MENS +15.16% GlobeNewswire
Nov-20	Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes MENS +12.44% GlobeNewswire
Sep-29	Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards MENS -16.30% GlobeNewswire
Sep-18	Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei MENS GlobeNewswire
Sep-16	Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention MENS +5.02% GlobeNewswire
Aug-22	Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP) MENS +6.58% GlobeNewswire
Jul-22	Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention MENS -8.55% GlobeNewswire
Jun-18	Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering MENS -20.87% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)